BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM | N221104 | GILEAD SCIENCES INC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9216996Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 19, 2033 | — | Yes | Yes | — | — |
| 9708342Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Jun 19, 2035 | — | Yes | Yes | — | — |
| 9732092Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 19, 2033 | — | Yes | Yes | — | — |
| 9951043Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Feb 28, 2034 | — | Yes | Yes | — | |
| 10071985Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 17, 2037 | — | Yes | Yes | — | — |
| 10385067Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Jun 19, 2035 | — | — | — | — | |
| 10654827Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 17, 2037 | — | — | — | — | |
| 11267799Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 16, 2038 | — | Yes | — | — | — |
| Code | Date | Status |
|---|---|---|
| NCENewly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 22, 2027 | Active |
| NPNewly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 27, 2029 | Active |
Gilead Sciences' BIXLENVO (bictegravir sodium/lenacapavir sodium) received new chemical entity exclusivity expiring Aug 2029.
New: BIXLENVO (BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM) — exclusivity NP exp 08/27/2029
Gilead's BIXLENVO (bictegravir sodium; lenacapavir sodium) received new chemical entity exclusivity expiring Dec 2027, blocking generic competition until that date.
New: BIXLENVO (BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM) — exclusivity NCE exp 12/22/2027